ストックスクリーナーアプリを入手
2.765
3.66%
-0.105
Biodexa Pharmaceuticals Plc Adr (BDRX) 最新ニュース
Result of Annual General Meeting - Yahoo Finance UK
Biodexa prices $3.5 million offering with warrants - Investing.com
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants - Yahoo Finance UK
symbol__ Stock Quote Price and Forecast - CNN
Biodexa expands Serenta phase 3 trial into Canada - Investing.com
Biodexa Pharmaceuticals plc Sponsored ADR Actuals & Estimates (NASDAQ:BDRX) - TradingView
Postponement and Re-scheduling of Annual General Meeting - markets.businessinsider.com
BDRX News | BIODEXA PHARMACEUTICALS-ADR (NASDAQ:BDRX) - ChartMill
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
BDRXBiodexa Pharmaceuticals Plc ADR Latest SEC Filings - Finviz
BDRX Stock Price, Quote & Chart | BIODEXA PHARMACEUTICALS-ADR (NASDAQ:BDRX) - ChartMill
Biodexa proposes share capital reorganization at June meeting - Investing.com UK
Biodexa issues letter to Shareholders - markets.businessinsider.com
Biodexa proposes share capital reorganization at June meeting By Investing.com - Investing.com Nigeria
Biodexa plans to shrink 373B shares without cutting ADS stakes - Stock Titan
BDRX Stock Jumps As Biodexa ADRs Lead Biotech Rally - StocksToTrade
BDRX Stock Jumps As ADR Momentum Attracts Active Traders - timothysykes.com
Biodexa Pharmaceuticals surges on pre-market trading - Intellectia AI
Inventory turnover of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Net income before discontinued operations of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Book value per share of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Biodexa Pharmaceuticals plc Sponsored ADR Cash Flow – FWB:5MP2 - TradingView — Track All Markets
Net debt of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Basic earnings per share (basic EPS) of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Price to earnings ratio of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Who's Buying or Selling Biodexa Pharmaceuticals PLC (STU:5MP2) Stock Today? - GuruFocus
Biodexa Pharmaceuticals Plc: Shareholders Board Members Managers and Company Profile | US59564R8723 - marketscreener.com
Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today? - Sahm
Why is Biodexa Pharmaceuticals (BDRX) stock skyrocketing today? - MSN
Biodexa partners with Syngene for MTX240 manufacturing By Investing.com - Investing.com Australia
171.7M Ordinary Shares resale prospectus — Biodexa (NASDAQ: BDRX) - Stock Titan
109.8M Ordinary Shares resale prospectus — Biodexa (NASDAQ: BDRX) - stocktitan.net
943.4M Ordinary Shares for Resale; Biodexa (NASDAQ: BDRX) resale filing - stocktitan.net
1.7018B shares for resale by holders — Biodexa (NASDAQ: BDRX) - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) registers 2.99M ADS for resale via equity line - Stock Titan
Biodexa’s eRapa Program: Global Expansion and European Gains - StocksToTrade
Biodexa partners with Syngene for MTX240 manufacturing - Investing.com
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies - ChartMill
BDRX SEC FilingsBiodexa Pharmaceuticals plc 10-K, 10-Q, 8-K Forms - Stock Titan
No approved FAP drug: Biodexa opens global eRapa access - Stock Titan
[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) registers 2.99M ADSs for resale under equity line - Stock Titan
943.4M Ordinary Shares resale by selling holders (NASDAQ: BDRX) - Stock Titan
Biodexa Pharmaceuticals (BDRX) flags going-concern doubts amid ongoing losses - Stock Titan
Biodexa (NASDAQ: BDRX) grows pipeline but warns on 2026 funding needs - stocktitan.net
Preliminary Results for the Year Ended 31 December 2025 - GlobeNewswire
Biodexa releases audited preliminary 2025 results for investors - Stock Titan
Biodexa partners with Tanner Pharma for FAP drug early access By Investing.com - Investing.com Australia
Biodexa Launches Global Early Access Program for eRapa for - GlobeNewswire
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group - markets.businessinsider.com
Biodexa partners with Tanner Pharma for FAP drug early access - Investing.com
Biodexa (NASDAQ: BDRX) director reports detailed stock option holdings - stocktitan.net
1.26%
3.59%
大文字化:
|
ボリューム (24 時間):